Jones Oliver M, John Solomon K P, Lawrance Richard J, Fozard J Basil J
Department of Colorectal Surgery, Royal Bournemouth Hospital, Bournemouth, UK.
Ann R Coll Surg Engl. 2007 May;89(4):414-7. doi: 10.1308/003588407X183382.
Ureteric obstruction is a potentially terminal event in patients with irresectable or recurrent colorectal cancer. Urinary tract obstruction is easily relieved by either two stage antegrade stenting or one stage retrograde stenting. However, there is little in the literature about outcomes after this procedure and it is unclear which, if any, patients should be offered this intervention.
This was a retrospective review of a prospectively collected database of patients diagnosed with colorectal cancer. This database comprised 1428 cases (operative and non-operative) diagnosed at a single institution. This was cross-checked with databases for patients undergoing nephrostomy and/or antegrade stenting and by clinical coding for those patients having retrograde stenting between January 1996 and October 2004.
Thirteen patients were identified (median age, 69 years: range, 35-85 years; 9 male). The aetiology of obstruction was recurrent tumour in 6 patients and irresectable tumour in the remaining 7 patients. Two patients were discussed at a urology multidisciplinary meeting before stenting and a further two were discussed with colorectal surgeons. One patient received a palliative cystectomy and ileal conduit for a vesicovaginal fistula followed by radiotherapy. Four patients received chemotherapy after stenting. Overall median survival was 210 days (range, 13-927 days).
Long-term survival is possible in selected patients with recurrent or irresectable colorectal cancer and malignant ureteric obstruction. This appears to be more likely in those patients in whom other treatments, particularly chemotherapy, are available.
输尿管梗阻是不可切除或复发性结直肠癌患者可能出现的终末期事件。尿路梗阻可通过两阶段顺行支架置入术或一阶段逆行支架置入术轻松缓解。然而,关于该手术后的结果,文献报道较少,目前尚不清楚哪些患者(如果有的话)适合接受这种干预措施。
这是一项对前瞻性收集的结直肠癌患者数据库进行的回顾性研究。该数据库包含在单一机构诊断的1428例病例(手术和非手术)。通过对接受肾造瘘术和/或顺行支架置入术患者的数据库进行交叉核对,并对1996年1月至2004年10月期间接受逆行支架置入术的患者进行临床编码。
共确定了13例患者(中位年龄69岁,范围35 - 85岁;9例男性)。梗阻病因中,6例为复发性肿瘤,其余7例为不可切除肿瘤。2例患者在支架置入术前在泌尿外科多学科会议上进行了讨论,另有2例与结直肠外科医生进行了讨论。1例患者因膀胱阴道瘘接受了姑息性膀胱切除术和回肠造口术,随后接受了放疗。4例患者在支架置入术后接受了化疗。总体中位生存期为210天(范围13 - 927天)。
部分复发性或不可切除性结直肠癌合并恶性输尿管梗阻的患者有可能获得长期生存。对于那些有其他治疗方法,特别是化疗可用的患者,这种可能性似乎更大。